Common drug linked to depression

Health professionals are being urged to be alert for signs of depressive disorder in women being treated for overactive bladder.

A study of almost 3000 Taiwanese women with the condition reveals that those prescribed antimuscarinics are 38% more likely to be diagnosed with depressive disorder than those not on the treatment.

While antimuscarinic drugs — including oxybutynin, tolterodine and trospium — are the mainstay of overactive bladder treatment. Large studies showing good efficacy, they can produce varying degrees of adverse effects, such as dry mouth, blurred vision, confusion, constipation and, rarely, tachycardia.

However, it is only now that the association between antimuscarinics and a subsequent risk of depressive disorder is becoming clear.

The results from the Taiwanese study show that women on antimuscarinics are 1.38 times more likely to be diagnosed with subsequent